• Leveljump Healthcare has secured a term loan commitment from TD Canada Trust for $3.2 million
  • The loan will allow the LevelJump to close the acquisition of three Ontario diagnostic imaging clinics
  • The loan facility will be a $3.2 million term loan, amortized over 10 years
  • TD Canada Trust is providing the company with a $150,000 operating line of credit
  • Leveljump Healthcare offers medical diagnostic imaging including teleradiology to client hospitals and imaging centers
  • Leveljump Healthcare Corp. (JUMP) is up 3.57 per cent on the day, trading at C$0.145 per share at 10:45 am EST

Leveljump Healthcare has secured a term loan commitment from TD Canada Trust for $3.2 million.

Combined with the company’s cash on hand, the term loan will allow LevelJump to close the previously announced acquisition of three Ontario diagnostic imaging clinics.

The loan facility will be a $3.2 million term loan, amortized over 10 years with an expected interest rate of less than 4 per cent. 

TD Canada Trust is providing the company with a $150,000 operating line of credit at prime +1.5 per cent.

“We are very excited to have TD Canada Trust act as our partner in this acquisition and we look forward to being able to present them with our additional acquisitions in the near future with a goal to expanding our relationship and building JUMP,” said Mitchell Geisler, Chief Executive Officer of Leveljump.

Leveljump Healthcare is focused on providing telehealth solutions as well as primary care services in radiology. As part of the company’s growth strategy, Leveljump is acquiring healthcare companies that have strong revenue and cash flow, with room for organic growth.

LevelJump Healthcare Corp. (JUMP) is up 3.57 per cent on the day, trading at C$0.145 per share at 10:45 am EST.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.